NPPB and hydrops fetalis: This effect may be related to its anti-aldosterone properties. Torsemide may result in a reduction of myocardial collagen accumulation and a diminution of collagen type I synthesis in patients with HF, which may help halt or prevent cardiac fibrosis and myocardial structure changes, which are the end-stage pathologies observed in HF patients. Oral torsemide may improve LV diastolic function and decrease the plasma B-type natriuretic peptide (BNP) concentration in patients with chronic HF already receiving angiotensin-converting enzyme inhibitor (ACEI).